Long-term study of dazodalibep in people with Sjögren's syndrome
Checks long-term safety of dazodalibep in adults with Sjögren's syndrome.
Plain-language title generated from the registry record
Registry title: A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)
Key facts
- Where
- Bydgoszcz, Cracow, Katowice, Lodz, Lublin, Malbork, Poznan, Warsaw, Wołomin, Wroclaw, and Wrocław, PolandSee the 26 sites
- Phase
- Phase 3
Where in Poland
- Medicover Integrated Clinical Services Sp. z o.o.Bydgoszcz, PolandNo longer taking part
- Szpital Uniwersytecki nr 2 im dr Jana Biziela w BydgoszczyBydgoszcz, PolandNo longer taking part
- Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k.Cracow, PolandNo longer taking part
- Malopolskie Centrum KliniczneCracow, PolandNo longer taking part
- Promed P.Lach R.Glowacki Sp. j.Cracow, PolandNo longer taking part
- Pratia S.A.Katowice, PolandNo longer taking part
- Futuremeds Sp. z o.o.Lodz, PolandNo longer taking part
- ETG LubllinLublin, PolandNo longer taking part
- Reumed Sp. z o.o.Lublin, PolandNo longer taking part
- Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Sp. z o. oMalbork, PolandNo longer taking part
- Med Polonia Sp z o.o.Poznan, PolandNo longer taking part
- Pratia S.A.Poznan, PolandNo longer taking part
- Prywatna Praktyka Lekarska Prof. dr hab. med. Pawel HrycajPoznan, PolandNo longer taking part
- Twoja Przychodnia Poznanskie Centrum Medyczne Sp. z o.o.Poznan, PolandNo longer taking part
- Etg Warszawa Sp. z o.o.Warsaw, PolandNo longer taking part
- Futuremeds Sp. z o.o.Warsaw, PolandNo longer taking part
- Klinika Reuma Park Sp. z o.o. S.K.Warsaw, PolandNo longer taking part
- Medicover Integrated Clinical Services Sp. z o.o.Warsaw, PolandNo longer taking part
- MTZ Clinical Research powered by PratiaWarsaw, PolandNo longer taking part
- Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory ReicherWarsaw, PolandNo longer taking part
- Wojskowy Instytut Medyczny Panstwowy Instytut BadawczyWarsaw, PolandNo longer taking part
- K2J2 Sp. z o.o.Wołomin, PolandNo longer taking part
- Centrum Medyczne OporowWroclaw, PolandNo longer taking part
- Futuremeds Sp. z o.o.Wroclaw, PolandNo longer taking part
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandNo longer taking part
- PRACOWNIA BADAŃ KLINICZNYCH SALUSWrocław, PolandNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT06747949EU 2024-517513-32-00
- Record updated
- 28 April 2026
- Original description
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.Read full original descriptionShow less
A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjögren's Syndrome (SS)
The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.
Inclusion: Participants are eligible to be included in the study only if all the following criteria apply:; Participant has provided informed consent before initiation of any study specific activities/procedures; Must have been eligible to receive and have received IP (dazodalibep or placebo) and completed the study (through Week 48) in one of the phase 3 SS dazodalibep studies (HZNP-DAZ-301, or HZNP-DAZ-303); Must be able to receive Dose 1 of this LTE study at the Week 48 Visit (+28 days) for the prior pivotal phase 3 SS dazodalibep studies (HZNP DAZ-301, or HZNP DAZ-303).
Exclusion: Individuals who plan to receive live (attenuated) vaccine during the LTE study; Female participants of childbearing potential unwilling to use protocol-specified method of contraception during treatment and for an additional 12 weeks after the last dose of investigational product; Clinically significant active infection at Day 1, in the opinion of the Investigator, including ongoing and chronic infection requiring antibiotics or antiviral medication; Any condition or change in health status observed or reported during the phase 3 SS studies (HZNP-DAZ-301, or HZNP-DAZ-303) that, in the opinion of the Investigator or the Sponsor, would interfere with evaluation and interpretation of participant safety or alter the risk-benefit associated with IP administration; History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation; Participants are excluded from the study if any of the following criteria apply:; Planned participation in another clinical study with an IP or procedure during the LTE study. Other investigational procedures and participation in observational research studies while participating in this study are excluded; Planned surgeries or hospitalizations that, in the opinion of the Investigator or the Sponsor, would interfere with evaluation and interpretation of participant safety; Female participants who are pregnant or lactating or planning to become pregnant during the study; Participant has known sensitivity to any of the products or components to be administered during dosing; Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.